New  	New  	 JJ	B-NP
oral  	oral  	 JJ	I-NP
anticoagulants 	anticoagulants 	 NN	I-NP
:  	:  	 :	O
recommendations 	recommendations 	 NNS	B-NP
,  	,  	 ,	O
precautions  	precautions  	 NNS	O
and  	and  	 CC	O
perspectives  	perspectives  	 NN	B-NP
for  	for  	 IN	O
use  	use  	 NN	O
In  	In  	 IN	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
studies 	studies 	 NNS	O
,  	,  	 ,	O
some  	some  	 DT	O
oral  	oral  	 JJ	B-NP
inhibitors  	inhibitors  	 NN	I-NP
of  	of  	 IN	O
both  	both  	 DT	O
thrombin  	thrombin  	 NN	B-NP
( 	( 	 -LRB-	O
dabigatran  	dabigatran  	 FW	B-NP
etexilate 	etexilate 	 FW	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
activated  	activated  	 JJ	O
factor  	factor  	 NN	B-NP
X  	X  	 NN	I-NP
( 	( 	 -LRB-	O
rivaroxaban 	rivaroxaban 	 UH	B-NP
,  	,  	 ,	O
apixaban 	apixaban 	 CD	B-NP
)  	)  	 -RRB-	O
have  	have  	 VBP	O
been  	been  	 VBN	O
employed  	employed  	 VBN	O
as  	as  	 IN	O
new  	new  	 JJ	O
anticoagulant  	anticoagulant  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
atrial  	atrial  	 JJ	B-NP
fibrillation  	fibrillation  	 NN	I-NP
or  	or  	 CC	O
acute  	acute  	 JJ	O
coronary  	coronary  	 JJ	B-NP
syndromes 	syndromes 	 NN	I-NP
.  	.  	 .	O
Such  	Such  	 JJ	O
new  	new  	 JJ	O
drugs  	drugs  	 NNS	O
have  	have  	 VBP	O
overcome  	overcome  	 VBN	O
a  	a  	 DT	O
series  	series  	 NN	O
of  	of  	 IN	O
limitations  	limitations  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
standard-of-care  	standard-of-care  	 JJ	B-NP
warfarin 	warfarin 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
argue  	argue  	 VBP	O
for  	for  	 IN	O
the  	the  	 DT	O
possibility  	possibility  	 NN	O
of  	of  	 IN	O
an  	an  	 DT	O
easy 	easy 	 JJ	O
,  	,  	 ,	O
widespread  	widespread  	 JJ	O
use  	use  	 NN	O
of  	of  	 IN	O
anticoagulation  	anticoagulation  	 NN	B-NP
in  	in  	 IN	O
vascular  	vascular  	 JJ	B-NP
medicine 	medicine 	 NN	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
to  	to  	 TO	O
this  	this  	 DT	O
end 	end 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
need  	need  	 VBP	B-NP
information  	information  	 NN	I-NP
on  	on  	 IN	O
management  	management  	 NN	O
of  	of  	 IN	O
bleeding  	bleeding  	 VBG	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
receiving  	receiving  	 VBG	O
these  	these  	 DT	O
drugs 	drugs 	 NNS	O
.  	.  	 .	O
Dabigatran  	Dabigatran  	 JJ	B-NP
etexilate 	etexilate 	 NN	I-NP
,  	,  	 ,	O
rivaroxaban  	rivaroxaban  	 NN	B-NP
and  	and  	 CC	O
apixaban  	apixaban  	 RB	O
affect  	affect  	 VB	O
major  	major  	 JJ	O
laboratory  	laboratory  	 NN	B-NP
tests  	tests  	 NNS	I-NP
for  	for  	 IN	I-NP
clotting 	clotting 	 NN	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
at  	at  	 IN	O
present  	present  	 JJ	O
we  	we  	 PRP	O
do  	do  	 VBP	O
not  	not  	 RB	O
know  	know  	 VB	O
whether  	whether  	 IN	O
and  	and  	 CC	O
how  	how  	 WRB	O
this  	this  	 DT	O
information  	information  	 NN	O
may  	may  	 MD	O
be  	be  	 VB	O
clinically  	clinically  	 RB	O
useful 	useful 	 JJ	O
.  	.  	 .	O
Their  	Their  	 PRP$	O
high  	high  	 JJ	O
cost  	cost  	 NN	O
is  	is  	 VBZ	O
another  	another  	 DT	O
major  	major  	 JJ	O
issue 	issue 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
newer  	newer  	 JJR	O
pharmacoeconomic  	pharmacoeconomic  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
are  	are  	 VBP	O
needed  	needed  	 VBN	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
their  	their  	 PRP$	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
ratio  	ratio  	 NN	I-NP
vs  	vs  	 NN	O
warfarin 	warfarin 	 NN	B-NP
.  	.  	 .	O
